Skip to content
Clinical Trials – home
ItalyBack to Italy

Clinical trials in Pozzuoli – page 41

1 231 clinical trials in Pozzuoli, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Pozzuoli at a glance
1 231
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 231 trials in Pozzuoli

Open in trial search

Atrial fibrillation

Not yet recruiting

Prevention of Stroke and Systemic Embolism in Atrial Fibrillation Patients Treated with REGN7508 (cenvacibart) versus Apixaban

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Regeneron Pharmaceuticals Inc.

Efficacy and Safety of Atumelnant, Hydrocortisone and Prednisone in Adults with ACTH‑Dependent Cushing’s Syndrome: A Phase 2/3 Dose‑Finding Study

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atumelnant
  • Sponsor:Crinetics Pharmaceuticals Inc.

Type 2 diabetes mellitus

Not yet recruiting

Study of zenagamtide versus insulin glargine in adults with type 2 diabetes and high cardiovascular risk uncontrolled on oral medications

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Insulin Glargine
  • Sponsor:Novo Nordisk A/S

Ocular myasthenia

Not yet recruiting

Phase 3 Open‑Label Extension Study of Long‑Term Safety and Efficacy of Rozanolixizumab in Adults with Ocular Myasthenia Gravis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Rozanolixizumab
  • Sponsor:UCB Biopharma

Arteriosclerosis

Not yet recruiting

A study to evaluate the effect of muvalaplin on reducing major cardiovascular events in adults with high levels of lipoprotein(a) and atherosclerotic cardiovascular disease.

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Muvalaplin
  • Sponsor:Eli Lilly & Co.

Parkinson's disease

Not yet recruiting

A study to test if BHV-8000 is effective and safe for adults with early Parkinson's disease

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ioflupane (123I)
  • Sponsor:Biohaven Therapeutics Ltd.

Arteriosclerosis

Not yet recruiting

Study of olpasiran to prevent first major cardiovascular events in people with high levels of lipoprotein(a)

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Olpasiran
  • Sponsor:Amgen Inc.

Psoriasis

Not yet recruiting

Study on the Effectiveness of JNJ-77242113 and Deucravacitinib for Treating Moderate to Severe Plaque Psoriasis in Adults

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Janssen Cilag International

Acute coronary syndrome

Not yet recruiting

Early LDL‑cholesterol reduction with rosuvastatin drug combination in patients with acute coronary syndrome

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Alirocumab
  • Sponsor:Azienda Ospedaliera Universitaria Federico II Di Napoli

Primary biliary cholangitis

Not yet recruiting

Saroglitazar hemimagnesium normalizes alkaline phosphatase in primary biliary cholangitis patients with incomplete response or intolerance to ursodeoxycholic acid

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Saroglitazar hemimagnesium
  • Sponsor:Zydus Therapeutics Inc.

Phase 2 Study of Weekly Ficerafusp Alfa + Pembrolizumab vs Alternative Dosing in First‑Line Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ficerafusp alfa
  • Sponsor:Bicara Therapeutics Inc.

Colorectal adenocarcinoma

Not yet recruiting

Phase 2 Study of ro7589831 with Pembrolizumab vs Pembrolizumab Alone in Adults with Advanced Colorectal Cancer (MSI‑High or dMMR)

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Vividion Therapeutics Inc.

Other cities in Italy

The busiest research cities in the country

All 230 cities in Italy

Clinical research in Pozzuoli

What the registry says about research in the country

01 Neoplasms

Clinical trial activity in Località la Schiana, Pozzuoli is strongly focused on cancer research, with studies examining how to improve treatment options for several advanced solid tumors. The main goal is to test new therapeutic strategies and refine existing combinations for better disease control and patient outcomes.

  • Colorectal cancer, including metastatic and unresectable forms
  • Metastatic castration-resistant prostate cancer
  • Metastatic renal cell carcinoma
  • Breast cancer with hormone receptor-positive, HER2-negative disease

These studies are exploring more effective ways to slow progression, overcome treatment resistance, and improve survival in patients with advanced neoplasms.

02 Digestive System Diseases

Several trials in this site concentrate on digestive system cancers, especially advanced colorectal cancer. Research is centered on evaluating treatment effectiveness and finding better options for patients whose disease has already progressed or carries specific genetic changes.

  • RAS-mutant metastatic colorectal cancer
  • RAS/BRAF wild-type metastatic colorectal cancer
  • Unresectable left-sided metastatic colorectal cancer
  • Patients with metastatic colorectal cancer

Across these studies, the focus is on improving tumor response, extending disease control, and identifying which patients may benefit most from targeted treatment approaches.

03 Analytical, Diagnostic and Therapeutic Techniques and Equipment

This research landscape also includes therapeutic techniques aimed at improving how treatments are delivered and how response is monitored. The trials are not only testing active therapies, but also looking for better ways to understand resistance, safety, and treatment benefit in real-world patients.

  • Biomarker research for resistance and treatment monitoring
  • Safety and tolerability comparisons between treatment strategies
  • Quality of life assessments during therapy
  • Therapy optimization in advanced cancer care

In this part of the research portfolio, investigators in Pozzuoli are helping shape more precise and patient-centered cancer care.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.